{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T20:33:29Z","timestamp":1668890009391},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T00:00:00Z","timestamp":1435276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s11046-015-9914-1","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T00:29:27Z","timestamp":1435192167000},"page":"187-192","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole"],"prefix":"10.1007","volume":"180","author":[{"given":"Jose F.","family":"Camargo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Yakoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hee","family":"Cho-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,26]]},"reference":[{"issue":"Suppl 1","key":"9914_CR1","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","volume":"54","author":"G Petrikkos","year":"2012","unstructured":"Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23\u201334.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"9914_CR2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2217\/fmb.13.78","volume":"8","author":"RE Lewis","year":"2013","unstructured":"Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol. 2013;8(9):1163\u201375.","journal-title":"Future Microbiol"},{"issue":"4","key":"9914_CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/myc.12149","volume":"57","author":"DP Kontoyiannis","year":"2014","unstructured":"Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance((R)): focus on mucormycosis. Mycoses. 2014;57(4):240\u20136.","journal-title":"Mycoses"},{"issue":"6","key":"9914_CR4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12262-012-0429-4","volume":"74","author":"R Kaushik","year":"2012","unstructured":"Kaushik R. Primary cutaneous zygomycosis in India. Indian J Surg. 2012;74(6):468\u201375.","journal-title":"Indian J Surg"},{"issue":"5","key":"9914_CR5","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","volume":"118","author":"DP Kontoyiannis","year":"2011","unstructured":"Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216\u201324.","journal-title":"Blood"},{"issue":"6","key":"9914_CR6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","volume":"30","author":"DP Kontoyiannis","year":"2000","unstructured":"Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851\u20136.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"9914_CR7","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1086\/430000","volume":"41","author":"SG Filler","year":"2005","unstructured":"Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis. 2005;41(Suppl 3):S208\u201312.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"9914_CR8","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261\u20135.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"9914_CR9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","volume":"70","author":"D Salmon-Ceron","year":"2011","unstructured":"Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9914_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","volume":"83","author":"S Tsiodras","year":"2008","unstructured":"Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181\u201394.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"9914_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/RHU.0b013e31815d3ddd","volume":"13","author":"H Gadadhar","year":"2007","unstructured":"Gadadhar H, Hawkins S, Huffstutter JE, Panda M. Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy. J Clin Rheumatol. 2007;13(6):361\u20132.","journal-title":"J Clin Rheumatol"},{"issue":"12 Suppl","key":"9914_CR12","first-page":"ECR51","volume":"91","author":"A Keijzer","year":"2006","unstructured":"Keijzer A, van der Valk P, Ossenkoppele GJ, van de Loosdrecht AA. Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha. Haematologica. 2006;91(12 Suppl):ECR51.","journal-title":"Haematologica"},{"issue":"3","key":"9914_CR13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1442-9071.2007.01458.x","volume":"35","author":"P Singh","year":"2007","unstructured":"Singh P, Taylor SF, Murali R, Gomes LJ, Kanthan GL, Maloof AJ. Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clin Exp Ophthalmol. 2007;35(3):275\u201380.","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"9914_CR14","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood-2003-01-0267","volume":"102","author":"FM Marty","year":"2003","unstructured":"Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102(8):2768\u201376.","journal-title":"Blood"},{"issue":"9","key":"9914_CR15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s10620-006-9455-z","volume":"52","author":"SM Devlin","year":"2007","unstructured":"Devlin SM, Hu B, Ippoliti A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn\u2019s disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci. 2007;52(9):2078\u201381.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"9914_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1155\/2013\/363250","volume":"24","author":"AJ Wright","year":"2013","unstructured":"Wright AJ, Steiner T, Bilawich AM, English JC, Ryan CF. Pulmonary mucormycosis in a patient with Crohn disease on immunosuppressive medications including infliximab. Can J Infect Dis Med Microbiol. 2013;24(2):67\u20138.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"3","key":"9914_CR17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000230676","volume":"80","author":"GC Wall","year":"2009","unstructured":"Wall GC, Leman BI. Mucormycosis in a Crohn\u2019s disease patient treated with infliximab. Digestion. 2009;80(3):182\u20134.","journal-title":"Digestion"},{"issue":"1","key":"9914_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/sur.2006.039","volume":"9","author":"E Odessey","year":"2008","unstructured":"Odessey E, Cohn A, Beaman K, Schechter L. Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg Infect. 2008;9(1):91\u20138.","journal-title":"Surg Infect"},{"issue":"3","key":"9914_CR19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1179\/joc.2009.21.3.272","volume":"21","author":"PE Verweij","year":"2009","unstructured":"Verweij PE, Gonzalez GM, Wiedrhold NP, Lass-Florl C, Warn P, Heep M, et al. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother. 2009;21(3):272\u201381.","journal-title":"J Chemother"},{"issue":"3","key":"9914_CR20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.03176-13","volume":"52","author":"D Peixoto","year":"2014","unstructured":"Peixoto D, Gagne LS, Hammond SP, Gilmore ET, Joyce AC, Soiffer RJ, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014;52(3):1016\u20139.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"9914_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11908-010-0129-9","volume":"12","author":"B Spellberg","year":"2010","unstructured":"Spellberg B, Ibrahim AS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep. 2010;12(6):423\u20139.","journal-title":"Curr Infect Dis Rep"},{"issue":"11","key":"9914_CR22","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","volume":"58","author":"DS Jung","year":"2014","unstructured":"Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014;58(11):6993\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"9914_CR23","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","volume":"67","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, Preston RA, O\u2019Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012;67(11):2725\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"9914_CR24","author":"U Durani","year":"2015","unstructured":"Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ. Posaconazole levels in patients taking the delayed-release tablet versus the oral suspension: a retrospective comparison. Antimicrob Agents Chemother. 2015. doi: 10.1128\/AAC.00496-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"9914_CR25","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/AAC.05000-14","volume":"59","author":"WM Kersemaekers","year":"2015","unstructured":"Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59(6):3385\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"9914_CR26","author":"A Cumpston","year":"2015","unstructured":"Cumpston A, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, et al. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob Agents Chemother. 2015. doi: 10.1128\/AAC.00581-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"9914_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/myc.12309","volume":"58","author":"MM Conant","year":"2015","unstructured":"Conant MM, Sha BE, Proia LA. Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis. Mycoses. 2015;58(5):313\u20134.","journal-title":"Mycoses"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-015-9914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-015-9914-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-015-9914-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T13:57:52Z","timestamp":1566914272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-015-9914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,26]]},"references-count":27,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["9914"],"URL":"https:\/\/doi.org\/10.1007\/s11046-015-9914-1","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,26]]}}}